This open label Phase 1 multicenter study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with pembrolizumab in participants with solid tumors in Part 1.~In Part 2, in the expansion cohort (Cohort A) we will assess the antitumor activity and safety of SAR442720 combined with pembrolizumab in participants with metastatic 1L lung cancer.~In Part 3, we will evaluate the safety, MTD, RP2D and antitumor activity of SAR442720 in combination with adagrasib in participants with lung cancer and KRAS G12C mutation.~In Part 4, we will evaluate the impact of the formulations (formulation 1 and formulation 2) and of the food on the PK of SAR442720 when dosed in combination with pembrolizumab. The expected duration of study intervention for participants may vary, based on progression date; median expected duration of study per participant is estimated to be about 10 months in Part 1, Part 3 and Part 4 (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up) and in Part 2 16 months (up to 1 month for screening, a median of 12 months for treatment and a median of 3 months for long term follow up.)
Primary Objectives:~Part 1~To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors.~To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors.~Part 2~To determine the anti-tumor activity of SAR442720 in combination with pembrolizumab.~Part 3A~To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC~To characterize the safety and tolerability of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC~Part 3B~To determine the anti-tumor activity of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC~Part 4~To evaluate the impact of food on the PK of SAR442720 when dosed with pembrolizumab.~To evaluate the impact of the formulations (formulation 1 and formulation 2) on the PK of SAR442720 when dosed with pembrolizumab.~Secondary Objectives:~Part 1~To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720.~To estimate the anti-tumor effects of SAR442720 with pembrolizumab.~Part 2~To assess the safety profile of SAR442720 combined with pembrolizumab.~To assess other indicators of anti-tumor activity.~To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720.~Part 3A~To characterize the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720.~To estimate the anti-tumor effects of SAR442720 with adagrasib~Part 3B~To assess the safety profile of SAR442720 with adagrasib in participants with KRAS G12C NSCLC.~To assess other indicators of anti-tumor activity.~To assess the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720.~Part 4~To assess the safety and tolerability of SAR442720 formulations with pembrolizumab~To estimate the anti-tumor effects of SAR442720 with pembrolizumab.